Atrium Therapeutics, Inc.

NASDAQ:RNA

Biotechnology

Healthcare
$6.64 +1.28%

+$0.16 today

Market cap
$143.23M
Beta
0.42
P/E (TTM)
-3.3
EPS (TTM)
-$3.78
52W Low $11.40High $16.77

Volume 0.22M

Average 0.35M

RNA Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Atrium Therapeutics, Inc.NASDAQ: RNA

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit of $19.48M in Q1 FY2026

Q1 FY2026 gross profit was $19.48M.

Context

  • Gross profit amounted to 100.0% of revenue in FY2025.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$19.48M+2168.2% QoQ
Last fiscal yearDec 2025
$18.62M— YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
18.62M USD
Year-over-year change
—

Gross Profit vs competitors

How RNA compares with its peers on the latest reported figures

No competitor Gross Profit figures are available to compare.

Atrium Therapeutics, Inc.

NASDAQ:RNA

Intrinsic Alpha fair value

Locked

Current Price

$6.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.